At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 21 enrolled
Drug / intervention
CNTO 2476 3.0 x 10^5 cells +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Multicenter, Double-masked, Randomized Study Evaluating the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Subjects With Visual Acuity Impairment Associated With Geographic Atrophy Secondary to Age Related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating CNTO 2476 3.0 x 10^5 cells and Subretinal Delivery System for Visual Acuity and 2 related conditions. Completed, enrolled 21 participants across 8 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and performance profile of the suprachoroidal surgical approach and the Delivery System.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVisual Acuity, Geographic Atrophy, Macular Degeneration
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartDec 2015
First PostedJan 2016
Primary CompletionJun 2019
TodayJul 2026
First PostedJan 20, 2016
Enrollment StartDec 4, 2015
Primary CompletionJun 5, 2019
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 10.5 years ago
Interventions
CNTO 2476 3.0 x 10^5 cellsdrug
Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10\^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
Subretinal Delivery Systemdevice
Participants will receive CNTO 2476 by using the Delivery System.